Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A Bejan, Eduardo Cardenas, Christina J Falcon, David M Faleck, Matthew A Gubens, Scott Huntsman, Douglas B Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M Lovly, Megan H Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M Balko, Geoffrey Liu, Melinda C Aldrich, Adam J Schoenfeld, Elad Ziv
Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) predisposes to IMC. In this study, we first develop a polygenic risk scores for CD (PRSCD ) and UC (PRSUC ) in cancer-free individuals and then test these PRSs on IMC in a cohort of 1316 patients with ICI-treated non-small cell lung cancer and perform a replication in 873 ICI-treated pan-cancer patients...
March 26, 2024: Nature Communications